Extended-Release Oxycodone Hydrochloride (Oxycontin®) for Cancer Pain Management: a Cost Analysis from the Brazilian Public and Private Healthcare Systems Perspectives

Stefani, S; Saggia, Mario; Naves, Andrea; Vasconcellos, J.F.; Teich, Vanessa

doi:10.1016/j.jval.2015.09.1107

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most studies comparing oral morphine and oxycodone were conducted in patients who had already a favorable response to opioid treatment [7,12,13], so they could not conclude which one of the two drugs can be considered superior to the other when used as "cancer pain titration" in clinical practice. A cost analysis of CR oxycodone for cancer pain management in Brazil demonstrated that CR oxycodone could lead to a reduction in total costs related to pain treatment in patients with cancer(392.66 BRL per patient), which would lead to resource savings for the payer [14]. Therefore, the costs are another important aspect to impact clinical treatment decision and rational drug use.…”

Section: Introductionmentioning

confidence: 99%

Oxycodone versus morphine for cancer pain titration: A systematic review and pharmacoeconomic evaluation

Jun-xiang

Wang

2020

PLoS ONE

View full text Add to dashboard Cite

To evaluate the efficacy, safety and cost-effectiveness of Oxycodone Hydrochloride Controlled-release Tablets (CR oxycodone) and Morphine Sulfate Sustained-release Tablets (SR morphine) for moderate to severe cancer pain titration. Methods Randomized controlled trials meeting the inclusion criteria were searched through Medline, Cochrane Library, Pubmed, EMbase, CNKI,VIP and WanFang database from the data of their establishment to June 2019. The efficacy and safety data were extracted from the included literature. The pain control rate was calculated to eatimate efficacy. Meta-analysis was conducted by Revman5.1.4. A decision tree model was built to simulate cancer pain titration process. The initial dose of CR oxycodone and SR morphine group were 20mg and 30mg respectively. Oral immediate-release morphine was administered to treat break-out pain. The incremental cost-effectiveness ratio was performed with TreeAge Pro 2019. Results 19 studies (1680 patients)were included in this study. Meta-analysis showed that the pain control rate of CR oxycodone and SR morphine were 86% and 82.98% respectively.

show abstract